Pharmaceutical product, containing a mixture of benzoic acid, phenol and an alkali fluoride, for the topical treatment of herpes virus efflorescences, and method for treatment of herpes simplex efflorescences in the human

ABSTRACT

The present invention relates to pharmaceutical products containing a mixture of benzoic acid, phenol and an alkali fluoride, in an aqueous or aqueous-alcohol solution, optionally in the presence of other usual additives for pharmaceutical preparations, in liquid or semi-liquid form, for the control of diseases in the human caused by herpes virus, and to methods for the topical treatment with these products of herpes simplex efflorescences in the human.

The present invention relates to a novel pharmaceutical productcontaining a mixture of benzoic acid, phenol and an alkali fluoride inan aqueous or aqueous-alcohol solution, optionally in the presence ofother usual additives for pharmaceutical preparations in liquid orsemi-liquid form, and its use for controlling herpes-virus-causeddiseases in the human.

Herpes-virus-caused diseases in the human generally induce a more orless pronounced formation of blisters, and especially on human mucousmembranes they cause the formation of sometimes very painful orextremely itchy blisters. A particularly well known form of suchdiseases is herpes simplex.

A product that contains both benzoic acid and phenol and sodium fluorideis on the market and is used highly diluted with water as a disinfectantfor the area of the mouth. Unexpectedly, mixtures of benzoic acid,phenol and an alkali fluoride, preferably sodium fluoride, in an aqueousor aqueous-alcohol solution, which optionally contains other usualadditives for pharmaceutical preparations in liquid or semi-liquid form,in a form not highly diluted with water, are suitable for rapid andeffective control of herpes-virus-caused diseases in the human, inparticular for external treatment of the diseased areas of the skin,especially mucous membrane areas.

The individual components are known in numerous pharmaceuticalpreparations. For instance, benzoic acid and phenol are used asantiseptics, and sodium fluoride is used for caries prevention.

The pharmaceutical product according to the invention for controllingherpes-virus-caused diseases in the human is characterized in that for100 g of end product, it contains, besides water or water-alcohol as asolvent and besides typical additives for pharmaceutical preparations inliquid or semi-liquid form, from 0.1 to 0.5 g of the alkali fluoride, inparticular sodium fluoride, preferably from 0.2 to 0.4 g of benzoicacid, from 0.6-0.8 g of phenol, and from 0.2 to 0.4 g of the alkalifluoride.

EXAMPLE 1

100 g of an aqueous solution contain 0.65 g of a 1:5 solution of benzoicacid in ethyl alcohol, 0.73 g of phenol and 0.22 g of sodium fluoride.The product additionally contains 5.88 g of menthol oil, 1.2 g of 01carbophylli, 1.63 g of methyl salicylate and 0.74 g of p-ethylhydroxybenzoate.

The ingredients are intimately mixed and poured into containers having astopper of a kind such that the stopper can be used to apply the productdrop by drop to the affected areas.

EXAMPLE 2

100 g of an aqueous solution contain 2.4 g of a 1:5 solution of benzoicacid in ethyl alcohol (0.4 g of benzoic acid and 2.0 g of 96% alcohol),1 g of phenol and 0.4 g of sodium fluoride. It contains no additives,for improving the odor, for example. The ingredients are processed as inexample 1.

I claim:
 1. A pharmaceutical product containing a mixture of benzoicacid, phenol and an alkali fluoride, in an aqueous or aqueous-alcoholsolution, optionally in the presence of other usual additives forpharmaceutical preparations, in liquid or semi-liquid form, for thetopical treatment of herpes virus efflorescences.
 2. A pharmaceuticalproduct as defined by claim 1, characterized in that the alkali fluorideis sodium fluoride.
 3. A pharamaceutcal product as defined by claim 1,characterized in that 100 g of the product contain from 0.1 to 0.5 g ofbenzoic acid, from 0.5 to 1.0 g of phenol and from 0.1 to 0.5 g of thealkali fluoride.
 4. A phamaceutical product as defined by claim 3,characterized in that 100 g of the product contains from 0.2 to 0.4 g ofbenzoic acid, 0.6 to 0.8 g of phenol and 0.2 to 0.4 g of the alkalifluoride.
 5. A method for the topical treatment of herpes simplexefflourescences, characterized in that a product defined by claim 1 isapplied to the efflorescence once or or a plurality of times.